Kornimate/medical-research-clean huggingface dataset:
a pap test intervention to enhance decision making among pacific islander women

Conditions: Cervical Cancer

Summary: this community-based randomized trial tested the effects of a social support intervention to increase chamorro, samoan, and tongan women's pap test behavior and social support among their male spouses or significant others in southern california.

the purpose of this five-year community-based randomized trial was to: 1) examine the pap test decision making process in pacific islander women; 2) assess the role of social support within the decision making process; and 3) develop and test an intervention to increase pap testing among pacific islander women, and support among their male spouses/significant others. the intervention was created utilizing a multi-attribute utility model and social support theory resulting in gender-specific educational workshops consisting of a social support intervention that informed both pacific islander women and men about cervical cancer and the importance of pap testing for pacific islander women, and aimed to increase social support among their male spouses/significant others.

Eligibility criteria:
inclusion criteria: * women ages 21 to 65 * of chamorro, samoan, and/or tongan ethnicity * has a significant other (married or in a long-term relationship for more than 5 years). exclusion criteria: * not a member of one of the churches or clans visited for recruitment

Keywords: cervical cancer screening pap test pacific islander americans
effectiveness and safety of campath in combination with tacrolimus monotherapy to prevent kidney graft rejection

Conditions: Kidney Transplantation

Summary: the purpose of this study is to determine whether campath following tacrolimus monotherapy is more effective in the prevention of renal graft rejection (considering an acute rejection rate of 5% for campath-1h/tacrolimus and of 22% for tacrolimus/mmf/steroids).

major advances in immunosuppressive therapy have resulted in long-term graft survival by the use of various drug combinations.however, these combinations carry the risk of e.g. infection, malignancy, renal damage, hypertension, diabetes, hyperlipidemia, hirsutism, cushingoid facial appearance and bone necrosis.therefore one of the major goals should be to reduce immunosuppression without increasing risk of rejections. based on good results of a pilot study (not a single acute rejection episode during the 18-20 months observation period despite low level of tacrolimus and absence of steroids) this randomised trial was designed to further evaluate the safety and efficacy of campath-1h.

Eligibility criteria:
inclusion criteria: * age 18-65 * endstage renal failure with no previous renal transplantation * cadaveric donor * written informed consent exclusion criteria: * pregnant or nursing women * multi-organ transplant recipients * live donor recipients * re-transplants * panel reactive antibodies (pra) \> 25% * previous treatment with campath-1h * use of other investigational agents within 6 weeks * active systemic infection * hiv positive patient or donor * positive lymphocyte cytotoxicity cross-match between recipient serum and donor cells * past history of anaphylaxis following exposure to humanized monoclonal antibodies

Keywords: campath-1h alemtuzumab tacrolimus renal transplantation immunosuppression prevention of acute rejection
customized crosslinking: safety and efficacy in an epithelium-off accelerated-pulsated protocol for thin keratoconus

Conditions: Keratoconus

Summary: the goal of this clinical trial is to document corneal ectasia stability in patients with keratoconus diagnosis treated with personalized cross linking energy. the main questions it aims to answer are: * is it effective while using personalized (reduced) energy? * is it safe for corneas thinner than 400 microns? participants will be treated with personalized energy corneal cross linking and posteriorly, will attend subsequent follow-up consults


Eligibility criteria:
inclusion criteria: * keratoconus diagnosed with corneal tomography/topography * thinnest point pachymetry below 400 microns exclusion criteria: * previous corneal cross linking history * corneal scars not allowing best corrected visual acuity of 20/100 or better * previous corneal hydrops history * psychomotor retardation history

Keywords: progression customized cross-linking
comparison of prolene thread seton vs silk thread seton for the treatment of perianal fistula

Conditions: Perianal Fistula

Summary: it is a randomized control trial in which we will treat the patients with perianal fistula with seton placement. we will divide the patients in two groups. group i will be treated with silk seton and group ii will be treated with prolene setone. the outcome will be then followed as fistula healing and recurrence.


Eligibility criteria:
inclusion criteria: * patients of both sexes and aged 20 years and above with high perianal fistula exclusion criteria: * low perianal fistulas fistulas due to chrons disease, tb or carcinoma
dydrogesterone-primed ovarian stimulation protocol versus gonadotropin releasing hormone antagonist protocol in icsi

Conditions: Ovary Cyst; Fertility Issues

Summary: gnrh antagonist protocol is currently a good strategy for controlled ovarian stimulation in women with pcos undergoing ivf/icsi cycles. finding a protocol that can be a better alternative will help in improving the success rate of ivf/icsi cycles

progesterone has potent restraint on hypothalamus-pituitary-ovarian axis. it acts on unidentified hypothalamic pulse oscillator neurons. in turn, it acts on gonadotropins releasing hormone (gnrh) secreting neurons leading to inhibition of gnrh secretion. this results in inhibition of both luteinizing hormone (lh) and follicle-stimulating hormone (fsh) secretion from anterior pituitary. the effect of progesterone appears to decrease gnrh pulse frequency which results in slowing down lh pulse frequency and reducing lh plasma concentrations

Eligibility criteria:
inclusion criteria: 1. all patients should be candidates for icsi. 2. age between 20-40 years. 3. body mass index 18-35 kg/m2. 4. diagnosis of pcos according to modified rotterdam's criteria exclusion criteria: * 1) any patient with contraindication to ivf treatment or pregnancy 2) women with history of intra-uterine abnormality. 3) severe endometriosis (grade 3 or 4) 4) clinically significant systemic disease or other endocrinopathy.

Keywords: ivf,icsi,success rate
cognitive therapy versus supportive therapy in borderline personality disorder

Conditions: Borderline Personality Disorder

Summary: this is a randomised trial comparing cognitive therapy and supportive therapy administered along one year in borderline personality disorder. the follow-up is one year after treatments end. the therapists were the same in the two groups. patients received one session a week during six months and one session every two weeks during the next six months

* cognitive therapy * structured session * conceptualization of the case with the patient * cognitive methods * guided discovery of the schemas * work on life-scenarios * from scenarios to schemas * empathic confrontation to the schemas * building new schemas (core belief work-sheet) * affective methods: role playing * interpersonal methods: counter transference issues * behavioral experiment * problem solving * consolidation methods * patients and therapists had manuals * supportive therapy * therapist: active listening (face to face) * empathy * unconditional positive regard * reformulation and clarification * reflection of the patient's feelings * reassurance * therapist emphasizes the importance to ventilate problems * therapist answers some factual questions * therapist politely ignore or refuse requests for advice and directive attitudes * therapist demonstrates warmth and genuineness * patients and therapists had manuals

Eligibility criteria:
inclusion criteria: * dsm-4 dibr \>=8 (diagnostic and statistical manual of mental disorders, fourth edition, diagnostic inventory for borderline-revised)

Keywords: borderline personality disorder controlled trials cognitive therapy supportive therapy suicide impulsivity
relationship of cricoid with the right and left bronchial diameters in the pediatric population using three-dimensional imaging.

Conditions: Larynx; Oxygen; Intubation

Summary: specific and objective guidelines for choosing endobronchial tube size for main-stem intubation in pediatric patients are lacking. the objective criteria for choosing an ett size for olv are likely to increase the safety and success. the primary aims of this study were to define the relationship between cricoid and mainstem bronchi (right and left) in children of various ages and to determine the effects of age, height and weight.

understanding the relationship between cricoid and mainstem bronchi can provide to be a useful adjunct for lung isolation in children. the relationship between cricoid dimensions and the dimensions of main-stem bronchi (right and left) have been studied using 2 dimensional ct images and video-bronchoscopic images. the present study defines the volume-based relationship between the right main-stem bronchus (rmsb), left main-stem bronchus (lmsb) and the cricoid ring based on 3 dimensional ct derived images. methods: the three dimensional ct images of 35 children, younger than 8 years, undergoing radiological evaluation unrelated to airway symptomatology were examined. the children were evaluated during spontaneous ventilation without airway devices either during natural sleep or with sedation. the 3-dimensional images of the airway column were evaluated at the level of cricoid, right mainstem bronchus and left main-stem bronchus, volumes were calculated and comparisons made between these levels. univariate and multivariate regression analysis was used to determine whether one or more of the variables (age, gender, height, weight and cricoid) had a predictable relationship to the rmsb and the lmsb diameter.

Eligibility criteria:
inclusion criteria: * children 1 month to 8 years of age exclusion criteria: * patients with tracheostomy tracheoesophageal fistula presence of mediastinal mass diaphragmatic hernia preterm infants
app-based intervention for treating insomnia among patients with epilepsy

Conditions: Epilepsy; Insomnia

Summary: sleep can affect frequency and occurrence of interictal spikes and occurrence, timing, and threshold of seizure. epilepsy can worsen sleep architecture and severity of sleep disorders. thus, a vicious cycle is set. certain epilepsy syndromes are so intertwined with sleep that they are considered sleep-related epilepsies. poor sleep in epilepsy is multifactorial and is worsened by poorly controlled seizures. app-delivered intervention has shown promise as a method to overcome health issues; however, the long-term effectiveness has not been proven in epileptic patients with chronic insomnia.


Eligibility criteria:
inclusion criteria: * are at least 18 years of age * diagnosis of epilepsy according to the international league against epilepsy criteria * self-report "moderate or severe" insomnia as indicated by a score of 15 or higher on the insomnia severity index * can speak, understand, and write in persian * no surgery planned in the next 6 months * have access to an android smartphone or a desktop computer with internet access * absence of major cognitive impairment or active psychiatric disorders exclusion criteria: * presence of a rapidly progressing neurological or medical disorder * a diagnosis of mental retardation * use of drugs or alcohol * untreated sleep apnea * current pregnancy
ang1005 in leptomeningeal disease from breast cancer

Conditions: Leptomeningeal Carcinomatosis; Leptomeningeal Metastases; Brain Metastases; HER2-negative Breast Cancer

Summary: this is an open-label phase 3 study to see if ang1005 can prolong survival compared to a physician best choice control in her2-negative breast cancer patients with newly diagnosed leptomeningeal disease and previously treated brain metastases.


Eligibility criteria:
inclusion criteria: 1. ≥ 18 years old 2. her2-negative breast cancer 3. at least 2 months of expected survival 4. newly diagnosed leptomeningeal carcinomatosis 5. documented history of brain metastasis that has been previously treated with radiation therapy 6. neurologically stable 7. eastern cooperative oncology group performance status grade ≤2 8. adequate laboratory test results prior to first dose 9. patients who are fertile must agree to remain abstinent or use reliable method of birth control exclusion criteria: 1. any prior treatment for leptomeningeal carcinomatosis, except emergency radiotherapy or shunt 2. prior treatment with ang1005 3. patients who have not had radiotherapy for their brain metastases 4. evidence of symptomatic intracranial hemorrhage or increased intracranial pressure 5. patients for whom intrathecal therapy is the most appropriate therapy for leptomeningeal disease 6. pregnancy or lactation and patients planning to be pregnant during the study 7. peripheral neuropathy \> grade 2 8. evidence of severe or uncontrolled diseases 9. presence of an infection including abscess or fistulae, or known infection with hepatitis b or c or hiv 10. history of interstitial lung disease 11. severe conduction disturbance 12. central nervous system disease requiring immediate neurosurgical intervention 13. known allergy to paclitaxel or any of its components 14. contra-indication for contrast-enhanced mri

Keywords: ang1005 leptomeningeal carcinomatosis leptomeningeal disease leptomeningeal metastases brain metastases her2-negative breast cancer targeted therapy
lithium versus lamotrigine in bipolar disorder, type ii

Conditions: Bipolar II Disorder

Summary: the investigators want in a 6-month randomized controlled trial (rct) to compare effects of lithium versus lamotrigine on mood stabilization and other critical patient outcomes in patients with bdii.

although bdii is more prevalent and with a higher disease burden, including more and longer depressive episodes and lower functioning, than bipolar disorder, type i (bdi), effects of pharmacological treatment including the most frequently used drugs in clinical practice lithium and lamotrigine, is substantially understudied. the investigators want in a 6-month randomized controlled trial (rct) to compare effects of lithium versus lamotrigine on mood stabilization and other critical patient outcomes in patients with bdii.

Eligibility criteria:
inclusion criteria: * bipolar disorder, type ii with diagnosis confirmed by scan interview * age 18-65 years * habile (i.e., able to give informed consent) * speaks danish exclusion criteria: * past non-response or intolerance to lamotrigine or lithium with \> 6 weeks treatment at an adequate dosage * currently taking mood stabilizers at enrollment in cadic * severe chronic kidney disease * severe cardiac insufficiency * brugadas syndrome * severe hypothyroidism despite treatment * women who are pregnant, breastfeeding or planning pregnancy in near future.
diastolic heart failure management by nifedipine

Conditions: Diastolic Heart Failure

Summary: patients with heart failure with preserved ejection fraction have a equally high risk for mortality and re-hospitalization as those with reduced ejection fraction. effective management strategies are critically needed to be established for this type of heart failure. these patients have more hypertensive and ischemic etiology than those with reduced ejection fraction. the investigators hypothesis is that ca channel blocker nifedipine can improve the heart failure clinical composite response endpoint compared with the conventional treatment in patients with heart failure with hypertension and/or coronary artery disease and preserved ejection fraction (\>=50%) by echocardiography. this study is multi-center, prospective, randomized, open-label, and blinded-endpoint design.


Eligibility criteria:
inclusion criteria: 1. 20 years and older 2. heart failure with history of hypertension and/or coronary artery disease 3. lvef \> or = 50% on echocardiography exclusion criteria: 1. valvular heart diseases with significant regurgitation and/or stenosis 2. hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and active myocarditis 3. constrictive pericarditis 4. cardiogenic shock 5. planned coronary artery bypass grafting or percutaneous coronary intervention within 3 months 6. history of acute coronary syndrome or stroke within 3 months 7. pregnancy or breastfeeding 8. hypersensitivity or contraindication to nifedipine 9. inability to obtain informed consent 10. any conditions not suitable for the participation in this trial judged by the investigator

Keywords: diastolic heart failure heart failure with preserved ejection fraction nifedipine
effect of complete decongestive therapy on carpal tunnel syndrome post upper limb lymphedema

Conditions: Lymphedema

Summary: this study will be conducted to investigate the therapeutic effect of complete decongestive therapy on carpal tunnel syndrome post-upper limb lymphedema.

lymphedema is a chronic condition characterized by lymphatic vessel ectasia and valve dysfunction, followed by the reflux of lymphatic fluid into the interstitial space. lymph stasis may lead to a chronic inflammatory process, resulting in adipose tissue differentiation and fibro adipose tissue deposition. one consequence of post-mastectomy lymphedema may be the development of nerve entrapments. one example is median nerve entrapment in the carpal canal, or carpal tunnel syndrome (cts). many studies assessed the relationship of cts as a risk factor for developing lymphedema, other studies stated the possibility of lymphedema as a potential contributor to cts development. complex decongestive treatment of breast cancer-related lymphoedema is an accepted strategy and is considered as an international standard for treatment. a previous review concluded that complex decongestive therapy has a positive impact on the volume of arm and quality of life in different stages of lymphedema.sixty females will be allocated randomly to two groups; first one will receive decongestive therapy and the second one will receive the routine medical treatment for ten weeks

Eligibility criteria:
inclusion criteria: * age will range between 20- 40 years. * only females will participate in the study. * all patients have carpal tunnel syndrome post upper limb lymphedema. exclusion criteria: * diabetes mellitus. * individuals with cardiopulmonary conditions. * individuals undergoing radiation therapy or chemotherapy. * hepatic or pancreatic diseases. * sensory impairment.

Keywords: complete decongestive therapy carpal tunnel syndrome upper limb lymphedema
effect of symptom management on inflammation and survival in metastatic lung cancer

Conditions: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung

Summary: there is a growing body of evidence that implicates inflammation as a mechanism of disease progression and reduced survival in patients with advanced cancer. elevated c-reactive protein levels have been shown to be associated with reduced performance status, specific cancer related symptoms and reduced overall survival. c-reactive protein levels are a surrogate for il-6 expression. il-6 is part of an inflammatory signature predicting cancer recurrence. veristrat® is a multivariate test which measures protein expression related to a host/tumor interaction mediated by inflammation. the investigators hope to examine the relationship between quality of life outcomes per fact-l survey and correlate them with changes in c-reactive protein levels and the veristrat® status. the hypothesis of this study is that the remarkable survival benefit in the temel study is mediated by reduced inflammation with improvement of symptom control.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of stage iv non-small cell lung cancer * eastern cooperative oncology group (ecog) performance status of 0, 1, or 2 * able to read and respond to questions in english exclusion criteria: * small cell lung cancer
the synchronized trial on expectant mothers with depressive symptoms by omega-3 pufas (synchro)in tokyo: open trial

Conditions: Depressive Symptoms

Summary: the present study aims to examine the efficacy and safety of omega-3 polyunsaturated fatty acids for pregnant women with depressive symptoms.


Eligibility criteria:
inclusion criteria: 1. pregnant women aged 20 years or older. 2. between 12-24 weeks gestation. 3. a japanese conversational ability to understand the scope of the present trial. 4. planned to return to the hospital for checkup at 4-6 weeks after childbirth. 5. an edinburgh postnatal depression scale (epds) score is 9 or more. 6. to have good physical health judged by obstetricians. exclusion criteria: 1. history and current suspicion of psychosis or bipolar i disorder or substance-related disorder or eating disorder or personality disorder. 2. the item of epds concerning suicide ideation is 2 or more. 3. other serious psychiatric symptoms such as self-harm behavior or in need of rapid psychiatric treatment. 4. difficult to expect a normal birth (ex: fetal malformation etc.). 5. having a history of bleeding disorder such as von willebrand's disease. 6. regular treatment with aspirin or warfarin within the last 3 months. 7. a smoking habit of ≥40 cigarettes per day. 8. regular treatment with ethyl icosapentate or regular consumption of omega- 3 pufa supplements within the last 3 months. 9. a habit of eating fish ≥4 times per week.